KIF20A and neoplasm: Using multiple TAAs in combination as targets drastically improved the outcome of anticancer immunotherapy (Fukushima et al, 2009), and therefore KIF20A could be not only a versatile tumour marker but also a TAA useful as a target of anticancer immunotherapy for pancreatic cancer by itself or in combination with other TAA(s).